Page 11234..1020..»

Category Archives: Eczema

Retrospective analysis of 397 DABE | CCID – Dove Medical Press

Posted: December 3, 2023 at 3:05 am

Introduction

Eosinophils have a wide range of biological functions and play an important role in anti-infection, inflammatory response, anti-tumor, and tissue damage and repair.1,2 Eosinophils enter the blood circulation after maturation in the bone marrow. There are no eosinophils in normal skin tissue, and eosinophils are recruited from peripheral blood to skin tissue only when inflammation occurs.3 Most dermatoses associated with blood eosinophilia (DABE) belong to allergy-related skin diseases, such as atopic eczema, contact dermatitis, urticaria, prurigo, and drug eruption; Second, blood eosinophilia can also be seen in parasitic infections and autoimmune bullous diseases. The skin is also the first and most commonly affected organ of hypereosinophilic syndrome (HES).4,5

It is estimated that for every additional eosinophil in the blood, there is a corresponding increase of 100 eosinophils in the tissue.6 Potential mechanisms leading to eosinophilia are divided into primary intrinsic mechanisms and secondary reactive mechanisms.7,8 The clonal expansion of eosinophils mediated by FIP1L1-PDGFRA (F/P) fusion gene belongs to the primary disease, while the secondary eosinophilia is mainly caused by eosinophilopoietic cytokines (IL-3, IL-5 and GM-CSF).7,9 The continuous increase of eosinophils can secrete a series of cytotoxic mediators, such as eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), and eosinophil peroxidase (EPO), leading to multiple organ damage and possibly life-threatening.10 However, the evaluation and treatment of dermatoses with blood eosinophilia is challenging because of the significant clinical and histopathological overlap between different DABE diseases.

In this study, we divided DABE patients into three groups according to blood absolute eosinophil count (AEC) levels: mild eosinophilia group, moderate eosinophilia group, and severe eosinophilia group, and summarized the demographics, clinical characteristics, laboratory results, related diagnoses, and treatments, hope to help the differential diagnoses of DABE patients to further optimize disease management.

This is a retrospective cross-sectional study, including all inpatients with AEC greater than or equal to 0.5109/L who visited the Department of Dermatology, Southwest Hospital of Army Military Medical University from January 2018 to January 2023. Since eosinophilia associated with dermatoses is usually not very high, the categorization used for HES does not make sense and important information in the mild to moderate group might have been overlooked.11 According to the degree of elevated blood AEC, patients were divided into the mild eosinophilia group (0.5 AEC109/L < 1.5), moderate eosinophilia group (1.5 AEC109/L < 3), and severe eosinophilia group (AEC109/L 3). Electronic medical records were reviewed for all cases, and data collected included demographics, patient history, clinical manifestations, laboratory results, diagnoses, and treatment. The Ethics Committee of Southwest Hospital of Army Medical University approved this study (KY2023100). Patient consent is not required for this retrospective study. The study conformed to the ethical guidelines of the Declaration of Helsinki.

Statistical analyses were performed using SPSS Statistics (V22; IBM SPSS Corp., Armonk, NY, USA). All tests were considered significant at P < 0.05. The KruskalWallis test was used to analyze variations in the age, duration of eosinophilia, serum total Immunoglobulin.E (IgE) values, and lactate dehydrogenase (LDH) values in different groups. Categorical data were analyzed using chi-square test or Fishers exact test, including sex ratios, medical history ratios, clinical manifestations (prevalence of pruritus, distribution of lesions, ratio of lesion types), diagnostic rates, and drug use rates.

A total of 397 DABE patients (267 males, 67.3%; median 59 years, range:4570 years) were included and grouped according to blood AEC: mild eosinophilia, 0.5 AEC < 1.5 (n = 292, 73.6%); moderate eosinophilia, 1.5 AEC < 3 (n = 70, 17.6%); severe eosinophilia, AEC 3 (n = 35, 8.8%, Table 1).

Table 1 Demographic and Historical Characteristics in the Study Groups

There were statistically significant differences in the age distribution (P = 0.012) and the proportion of atopic history (P < 0.001) among the three groups. The severe eosinophilia group had a higher proportion (23/35, 71.5%) of old patients and a lower proportion (1/35, 2.9%) of atopic history. 18.2% (66/397) of the patients had lesions associated with elevated blood eosinophils due to drug exposure. The proportion of drug sensitization in the severe eosinophilia group (10/35, 32.3%) was higher than that in the other two groups, but the difference was not statistically significant (P = 0.076). The severe group had the shortest duration of eosinophilia compared with the mild and moderate groups (P = 0.005, Table 1).

Almost all DABE patients (383/397, 96.5%) exhibited pruritus symptoms, which were independent of blood eosinophil levels (P = 0.549). Localized skin lesions were more common in the mild eosinophilia group, while generalized skin lesions were observed in the moderate and severe eosinophilia groups (P < 0.001). The morphological spectrum of skin lesions in DABE patients was wide, and the most common lesions were erythema (348/397, 87.7%) and papules (208/397, 52.4%). The incidence of skin vesicles was significantly higher in the moderate eosinophilia group than in the mild and severe groups (P = 0.03, Table 2). The incidence of other lesion types was independent of blood eosinophil levels.

Table 2 Clinical Manifestations in the Study Groups

We selected two blood parameters, serum total IgE and LDH, to analyze their association with blood eosinophilia. Serum total IgE was elevated in 68.4% (132/193) of DABE patients, and LDH levels were elevated in 27.7% (67/242) of DABE patients. In the mild eosinophilia group, the serum total IgE median was significantly lower than those in the other two groups (P < 0.001). In contrast to mild and moderate groups, elevated LDH was more common in the severe group, and their LDH levels were also higher (P < 0.001, Table 3).

Table 3 The Laboratory Results in the Study Groups

Then, we were interested in whether increased blood eosinophilia corresponded to eosinophilic infiltration in the skin and bone marrow. Histopathological examination of skin biopsies showed cutaneous eosinophilic infiltration in 71.9% (105/155) patients. There was no significant difference in skin eosinophil infiltration among the three groups (P = 0.629). The most common histopathologic characteristics are spongiosis and hyperplasia. Bone marrow biopsy histopathology showed that 93.2% (41/44) of DABE patients were accompanied by bone marrow eosinophil infiltration, and most of them were from the moderate or severe eosinophilia groups (Table 3). Screening for the F/P fusion gene, which has been associated with HES, was negative in 2 patients. For the immunophenotype analysis of peripheral blood lymphocytes, no abnormal T and B lymphocytes were found in all 3 patients.

The most common diagnosis in DABE patients was eczema/dermatitis (207/397, 52.1%), followed by drug eruption (66/397, 16.6%), systemic disease (50/397, 12.6%) including HES or tumor, autoimmune bullous diseases (34/397, 8.6%), psoriasis (23/397, 5.8%), and other diseases (17/397, 4.3%). The diagnosis of eczema/dermatitis was dominant in the mild eosinophilia group (P < 0.001), while the diagnosis of systemic disease (HES or tumor) was more common in the severe eosinophilia group (P < 0.001, Table 4).

Table 4 Final Diagnoses in the Study Groups

In this study, we also evaluated the response to therapeutic drugs in three groups with elevated blood eosinophils. Glucocorticoids (370/392, 93.2%) were the most commonly used drug to treat DABE, followed by antihistamines (322/397, 81.1%), immunosuppressants (129/392, 32.5%), antibiotics (14/392, 3.5%), retinoids (14/392, 3.5%), biologics (5/392, 1.3%), other drugs (7/392, 1.8%). In the mild eosinophilia group, the usage rate of antihistamines was significantly higher than that in the moderate and severe groups (P = 0.032), while the usage rate of antibiotics was opposite (P < 0.001, Table 5). There was no statistically significant difference in the usage rate of other drugs among the three groups.

Table 5 Treatment in the Study Groups

An elevated level of blood eosinophils may be the first important clue in a laboratory result. We analyzed in detail the demographics, clinical characteristics, laboratory results, related diagnoses and treatments in DABE patients. Our results demonstrated that blood eosinophil level is associated with different clinical types in DABE patients. Blood eosinophil level plus other information such as age, history of atopy, history of drug sensitization, disease duration, distribution of skin lesions, and abnormal blood parameters may be helpful for further diagnosis.

Our study revealed three distinct patterns: (1) Mild eosinophilia associated with localized skin lesions, atopic history, mildly elevated total serum IgE level, diagnosed with eczema/dermatitis, and frequent antihistamines use. (2) Moderate eosinophilia has the characteristics of both mild group and severe group. (3) The severe eosinophilia group had a high proportion of elderly people without atopic history, but with acute onset, generalized skin lesions, and high blood LDH levels, and the majority of them were diagnosed with systemic diseases (HES or tumor) (Figure 1).

Figure 1 The characteristics of demographics, history, lesion manifestation, examination, and diagnoses in DABE patients with mild, moderate, and severe blood eosinophilia. (-) The laboratory result was negtive. The laboratory result was mildly elevated. The laboratory result was dramatically elevated.

Abbreviations: DABE, dermatoses associated with blood eosinophilia; IgE, immunoglobulin E; LDH, lactate dehydrogenase.

The predominance of eosinophils in eczema is not surprising since T helper 2 (Th2) lymphocytes always induce the recruitment of eosinophils in inflamed areas.12 Dermatological results showed that eosinophil activation and toxic granule protein deposition were involved in the acute and chronic lesions of atopic eczema.13 Cetinkaya et al suggested that transient, mild eosinophilia in children is associated with atopic eczema, whereas persistent, severe eosinophilia may be associated with congenital immune deficiency.14 This is similar to our data, where patients under the age of 18 were mostly clustered in the mild eosinophilia group and were diagnosed with eczema. Our results also show that atopic eczema is often related to mild blood eosinophilia, and this relation is more pronounced when accompanied by atopic history and mildly elevated serum total IgE.15

The skin is one of the organs most commonly affected by adverse drug reactions (ADRs). Eosinophils play a key role in drug-induced lesions.16 The incubation period for drug exposure can vary from days to years. Correspondingly, the duration of drug eruption includes acute exacerbation and chronic relapse. Our study showed that 16.6% (66/397) of the patients had lesions and different degrees of elevated blood eosinophils due to drug exposure. The incidence of drug sensitization was 14.7%, 18.6%, and 28.6% in the mild, moderate, and severe eosinophilia groups, but there was no statistical difference among the three groups. Severe eosinophilia with organ damage of the heart, liver, and kidney is associated with more serious systemic adverse drug reactions, such as drug eruption with eosinophilia and systemic symptoms (DRESS).17 Similar to the study of Yang et al, we suggested that the circulating eosinophil count was positively correlated with the severity of drug eruption, and the circulating eosinophil count could also be a prognostic indicator of drug eruption.18 Therefore, any patient with unexplained eosinophilia must obtain a detailed medication history.

Although eosinophilia is generally considered to be insignificant in psoriasis, our results showed 22 cases of psoriasis with mild eosinophilia, including 14 cases of vulgaris, 5 cases of pustulosa, 3 cases of erythrodermic. Retinoids are the first-line drugs for the treatment of psoriasis. Correspondingly, the use of retinoids is clustered in the mild eosinophilia group. There are no published reports investigating the overall incidence of eosinophilia associated with psoriasis. In psoriasis patients, the number of eosinophils labeled with ECP polyclonal antibody was significantly higher than that in healthy controls.19 Sueki et al reported a case of psoriasis vulgaris in which peripheral blood eosinophilia paralleled with the Psoriasis Area and Severity Index (PASI) score, and improvement in psoriasis was directly correlated with decline in eosinophilia.20 Another study showed that peripheral blood eosinophilia appears to be associated with severe forms of psoriasis, such as generalized pustulosa and erythrodermic forms.6 In conclusion, the combination of mild blood eosinophilia and psoriasis appears to be a relatively common condition. It would be significant to further investigate this association in a larger series of cohorts.

Although parasitic infection is one of the most important causes of eosinophilia,21 only 1% (4/397) of DABE in our study were caused by parasitic infection (including 1 case of hookworm infection, 1 case of insect bite dermatitis, 2 cases of scabies) and both were from the mild eosinophilia group. It was reported that 1.0% of children with eosinophilia had parasitic infections, compared with 4.8% of non-parasitic infections.14 In another study, the frequency of parasitic infections in hypereosinophilia was 5.7%.22 Differences between these studies may be strongly related to various socioeconomic levels. Based on the epidemiological importance of parasitic infection, we suggest that for DABE patients with a history of travel to endemic areas and persistent eosinophilia, it is necessary to develop further stool and dermatoscopy to detect eggs and parasites.

Peripheral blood eosinophilia has been reported in 61% of bullous pemphigoid (BP) cases and 46% of pemphigus cases.23,24 In our study, 8.6% (34/397) of DABE patients were diagnosed with autoimmune bullous diseases. Research has shown the strong relation between circulating eosinophil counts and the classic phenotype of BP (vesicles and erosions).25 There was a positive correlation between the severity of BP and peripheral blood eosinophils in the study of Gore Karaali et al.26 Diagnosis of autoimmune bullous disease was mostly in the moderate eosinophilia group through semantic connectivity map analysis.27 Unfortunately, we did not detect these patterns, which may be due to the lack of enough patients with autoimmune bullous disease in our cohort.

In the severe eosinophilia group, DABE patients were more diagnosed with systemic diseases (HES and tumor), and they had a lower proportion with atopic history and a higher proportion of older age. Severe blood eosinophilia was associated with higher levels of IgE and LDH. HES is a diagnosis of exclusion, excluding allergies, infections, rheumatism, and other diseases.28 In various studies, more than 50% of patients with HES develop pleomorphic skin lesions, often delaying diagnosis and treatment.29,30 Khallaayoune et al reported a case diagnosed with BP who showed resistance to conventional treatment and persistent eosinophilia, and finally this patient was considered as BP-associated HES.31 Patients with HES should be carefully examined, especially bone marrow biopsy, F/P fusion gene, and immunophenotyping of peripheral blood lymphocytes. Because HES with the fusion gene is at risk of developing to the malignant end, eventually progressing to eosinophilic leukemia. It is worth noting that some HES patients have allergies, rhinitis, asthma, and other comorbidities at the same time, which is difficult to distinguish from atopic eczema.30

This study could help to better understand the relationship between dermatoses and blood eosinophilia, potentially improving diagnoses and treatments for patients. The level of blood eosinophilia corresponds to different dermatoses, and careful history and targeted examination are crucial for differential diagnosis.

This study was approved by the Ethics Committee of Southwest Hospital of Army Medical University (KY2023100). This retrospective study conformed to the ethical guidelines of the Declaration of Helsinki, and patients privacy and personal identity information are protected. Exemption from informed consent will not have any adverse impact on patients health and rights. Therefore, the patient consent is not required for this retrospective study.

The authors thank all participants in this study for their enthusiastic cooperation.

This research was funded by Natural Science Foundation of China (82073442).

The authors report no conflicts of interest in this work.

1. Wechsler ME, Munitz A, Ackerman SJ, et al. Eosinophils in health and disease: a state-of-the-art review. Mayo Clin Proc. 2021;96(10):26942707. doi:10.1016/j.mayocp.2021.04.025

2. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147174. doi:10.1146/annurev.immunol.24.021605.090720

3. Long H, Zhang G, Wang L, Lu Q. Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(2):189213. doi:10.1007/s12016-015-8485-8

4. Leiferman KM, Peters MS. Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract. 2018;6(5):14621482.e1466. doi:10.1016/j.jaip.2018.06.002

5. Radonjic-Hoesli S, Brggen MC, Feldmeyer L, Simon HU, Simon D. Eosinophils in skin diseases. Semin Immunopathol. 2021;43(3):393409. doi:10.1007/s00281-021-00868-7

6. Mansur AT, Gktay F, Yaar SP. Peripheral blood eosinophilia in association with generalized pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2008;22(4):451455. doi:10.1111/j.1468-3083.2007.02489.x

7. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(1):129148. doi:10.1002/ajh.26352

8. Leru PM. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy. 2019;9(1):36. doi:10.1186/s13601-019-0277-4

9. Hougaard M, Thomsen GN, Kristensen TK, et al. A retrospective cohort study of patients with eosinophilia referred to a tertiary centre. Dan Med J. 2022;69(4): A07210558

10. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014;289(25):1740617415. doi:10.1074/jbc.R113.546218

11. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607612.e609. doi:10.1016/j.jaci.2012.02.019

12. Akdis CA, Arkwright PD, Brggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):15821605. doi:10.1111/all.14318

13. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol. 2001;145(5):720729. doi:10.1046/j.1365-2133.2001.04456.x

14. Cetinkaya PG, Aytekin ES, Esenboga S, et al. Eosinophilia in children: characteristics, etiology and diagnostic algorithm. Eur J Pediatr. 2023;182(6):28332842. doi:10.1007/s00431-023-04961-x

15. Crnkovi HT, Bendelja K, imi Klari A, Tomi Raji M, Drkulec V, Aberle N. Family history and cord blood eosinophil count as predictors for atopic manifestations. Cent Eur J Public Health. 2019;27(4):267271. doi:10.21101/cejph.a5601

16. Hoetzenecker W, Ngeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38(1):7586. doi:10.1007/s00281-015-0540-2

17. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):19962011. doi:10.1016/S0140-6736(16)30378-6

18. Yang J, Yang X, Li M. Peripheral blood eosinophil counts predict the prognosis of drug eruptions. J Investig Allergol Clin Immunol. 2013;23(4):248255.

19. Kim TY, Park HJ, Kim CW. Eosinophil cationic protein (ECP) level and its correlation with eosinophil number or IgE level of peripheral blood in patients with various skin diseases. J Dermatol Sci. 1997;15(2):8994. doi:10.1016/S0923-1811(97)00614-2

20. Sueki H, Nakada T, Iijima M. A case of psoriasis vulgaris with peripheral blood eosinophilia, parallelling the psoriasis area and severity index (PASI) score. Clin Exp Dermatol. 2004;29(5):549550. doi:10.1111/j.1365-2230.2004.01566.x

21. Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338(22):15921600. doi:10.1056/NEJM199805283382206

22. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):922. doi:10.1038/nri3341

23. Crotty C, Pittelkow M, Muller SA. Eosinophilic spongiosis: a clinicopathologic review of seventy-one cases. J Am Acad Dermatol. 1983;8(3):337343. doi:10.1016/S0190-9622(83)70036-8

24. Morais KL, Miyamoto D, Maruta CW, Aoki V. Diagnostic approach of eosinophilic spongiosis. An Bras Dermatol. 2019;94(6):724728. doi:10.1016/j.abd.2019.02.002

25. Garrido PM, Aguado-Lobo M, Espinosa-Lara P, Soares-Almeida L, Filipe P. Association of peripheral blood and cutaneous eosinophils with bullous pemphigoid disease severity and treatment outcomes. Actas Dermosifiliogr. 2022;113(9):881887. doi:10.1016/j.ad.2022.05.021

26. Gore Karaali M, Koku Aksu AE, Cin M, Leblebici C, Kara Polat A, Gurel MS. Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid. Australas J Dermatol. 2021;62(2):e236e241. doi:10.1111/ajd.13547

27. Radonjic-Hoesli S, Martignoni Z, Cazzaniga S, et al. Characteristics of dermatological patients with blood eosinophilia: a retrospective analysis of 453 patients. J Allergy Clin Immunol Pract. 2022;10(5):12291237.e1228. doi:10.1016/j.jaip.2022.02.018

28. Salomon G, Severino M, Casassa E, et al. Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: a retrospective cohort study. Ann Dermatol Venereol. 2022;149(2):139141. doi:10.1016/j.annder.2021.12.002

29. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):13191325.e1313. doi:10.1016/j.jaci.2009.09.022

30. Neve S, Beukers S, Kirtschig G. Hypereosinophilic syndrome in an atopic patient. Clin Exp Dermatol. 2009;34(8):e643646. doi:10.1111/j.1365-2230.2009.03356.x

31. Khallaayoune M, Sialiti S, Meziane M, Senouci K. Bullous pemphigoid-like rash revealing hypereosinophilic syndrome. BMJ Case Rep. 2021;14(6). doi:10.1136/bcr-2021-242695

See the original post here:
Retrospective analysis of 397 DABE | CCID - Dove Medical Press

Posted in Eczema | Comments Off on Retrospective analysis of 397 DABE | CCID – Dove Medical Press

Derm In The News: November 26-December 2 – Dermatology Times

Posted: at 3:05 am

Carle Illinois College of Medicine: Skin in the Game: CI MED Student Launches Free Dermatology and Wound Care Clinic

A physician innovator from the Carle Illinois College of Medicine is launching Urbana-Champaigns first-ever free clinic focused on skin care. The Skin and Wound Care Community Clinic aims to address care gaps and provide accessible, culturally competent dermatological and wound care services to underserved populations, including under- and uninsured patients, homeless individuals, and those with limited access to healthcare. The clinic, set to open in the spring of 2024, will offer services such as skin and wound exams, skin cancer screenings, diabetic foot exams, skin biopsies, and patient education on preventing skin cancer and pressure injuries.

The landscape of cosmetic dermatology in India is undergoing a transformative shift as clinics actively seek the latest technologies and innovations to enhance natural aesthetics. Regenerative medicine is at the forefront of this revolution, offering treatments such as stem cell therapy, exosomes therapy, and advanced platelet-rich plasma (PRP) therapy like Growth Factor Concentrate (GFC). These therapies not only accelerate natural healing processes but also provide solutions for aging, hair loss, and facial rejuvenation.

Top headlines from this week to share with your patient:

Mohiba Tareen, MD, of Tareen Dermatology, who introduced the most advanced non-surgical treatment for common skin cancer in Wright County, Minnesota Image-Guided Superficial Radiation Therapy. This non-invasive treatment involves multiple visits and sessions but is described as quick and simple. The technology, brought to Wright County by SkinCure Oncology, uses ultrasound imaging to direct low-level x-rays to targeted areas of the skin, offering a 99.3% cure rate for early-stage non-melanoma skin cancer. With Minnesota ranking high in skin cancer cases, Tareen emphasizes the importance of this tool in treating skin cancer in the region.

A woman in Edinburgh, UK, waited almost four years to see an NHS dermatologist for her severe psoriasis. Initially diagnosed in 2017, she was referred for light therapy in 2019 but began treatment only in September 2023. The delay, exacerbated by COVID-19, reflects a broader issue of long waits for dermatology services in the NHS, with over 8,000 people joining the waiting list for a dermatology outpatient appointment.

Have you seen any dermatology headlines this week that we may have missed? Share with us by emailing our team atDTEditor@mmhgroup.com.

View post:
Derm In The News: November 26-December 2 - Dermatology Times

Posted in Eczema | Comments Off on Derm In The News: November 26-December 2 – Dermatology Times

When is the Best Time to Try Alternative Treatments for Eczema? – National Eczema Association

Posted: September 23, 2023 at 9:58 am

Articles

By Mollie Barnes

Published On: Sep 18, 2023

Last Updated On: Sep 18, 2023

Eczema is a complex condition that affects different people in different ways. For some people, moisturizing and/or medications might help clear up eczema symptoms enough to improve their daily quality of life. However, for others, especially for those with severe eczema, it might not be enough.

Oftentimes, people with severe eczema might be told by their doctor that they have tried everything for their eczema and that theres nothing left to try. This instance is often a good time to look to alternative therapies, said Dr. Peter Lio, a dermatologist and clinical assistant professor ofdermatologyandpediatrics at Northwestern University.

I think that incorporating alternative therapies with conventional ones which is, incidentally, how I define integrative dermatology is incredibly important and can make a real difference for many patients, said Dr. Lio, who is also the co-founder and co-director of the Chicago Integrative Eczema Center. In part, I think the willingness to try something different, gentler and out-of-the-box can often inspire hope and confidence. I also truly believe that there are many approaches that are off the beaten path that can make a real impact and are worth consideration.

Alternative treatments are generally considered to be anything outside Western medicine. For example, Traditional Chinese Medicine has been treating eczema for over 4,000 years, said Dr. Olivia Hsu Friedman, a doctor of acupuncture, Traditional Chinese Medicine and herbal medicine at Amethyst Holistic Skin Solutions in Naperville, Illinois.

Alternative treatments could range from anything like herbs or botanicals, to acupuncture, vitamins or sound therapy. It can also be something as simple as changing the type of clothing youre wearing.1

What usually happens is that patients are not aware of alternative therapies because they are typically first diagnosed by their MD dermatologists, who will proceed to treat them with traditional pharmacologic treatments, said Dr. Friedman.

Its usually after a patient has tried several traditional pharmacologic treatments and have not found them to be adequate solutions either because they dont work for them or they experience significant side effects that patients typically start opening their minds to other ways to treat their eczema, she said.

Patients can try alternative therapies at any time during their eczema journey, Dr. Friedman said. The most important thing is to find the solution that works best for that patient while considering the patients skin condition, financial situation, response to that medicine, overall health and emotional/psychological situation.

No matter your age, there are alternative therapies for you to try to treat your eczema.

What works for one person does not work for all, Dr. Friedman said. Other factors to consider beyond timing when determining whether or not to try alternative therapies include:

Generally, this is the worst time to try them, Dr. Lio said. My general approach is to get people better ideally much better, or even clear, using all the best tools in our toolbox. Once they are better, the goal is to try to minimize the use of more powerful therapies, and that is where I think the more alternative treatments can really play an important role.

Absolutely! said Dr. Lio. Just because something is natural (and that is a loaded term since even botanical supplements are generally not seen in nature in a capsule form) does not mean it is safe. There are numerous potential issues even with what appear to be safe and natural treatments, from contact dermatitis to true systemic toxicity and interactions with conventional medications, he said. So, it is important to discuss exactly what is going on so that everyone is on the same page.

Trying alternative therapies can be beneficial for people who are dealing with chronic eczema.

Sometimes, if things are really bad at the start, we need to lean heavily on more powerful conventional medications to get things calmed down, Dr. Lio said. But, over time, I find that I can leverage some of my integrative approaches to decrease and sometimes even stop conventional medications, which is truly exciting!

1. Ma, H, Shi V, Lio, PA. A multidisciplinary toolbox for atopic dermatitis treatments. Practical Dermatology. February 2021: 25-33. https://practicaldermatology.com/articles/2021-feb/a-multidisciplinary-toolbox-for-atopic-dermatitis-treatments Accessed September 1, 2023.

Excerpt from:
When is the Best Time to Try Alternative Treatments for Eczema? - National Eczema Association

Posted in Eczema | Comments Off on When is the Best Time to Try Alternative Treatments for Eczema? – National Eczema Association

How Eczema Negatively Impacted the Way She Talked to Herself – National Eczema Association

Posted: at 9:58 am

Articles

By Anne Marre Bautista, as told to Jennifer Moncayo-Hida

Published On: Sep 18, 2023

Last Updated On: Sep 18, 2023

Toxic self-talk is when your inner voice is excessively negative to yourself. For 35-year-old Anne Marre Bautista, from Los Angeles, her childhood experiences with eczema left her with a harsh inner critic that at one point made it hard for her to even look in the mirror. Here, in her own words, Bautista who has atopic dermatitis, contact dermatitis, dyshidrotic eczema, seborrheic dermatitis and hand eczema shared how she worked to overcome her negative self-talk and show herself more love.

I was diagnosed with eczema at 6 months old. My eczema played a large part in the way I talked to myself as a kid. I didnt realize this until I became an adult, but my self-hate actually began at a very young age. I used to be a cheerful and friendly kid. But when my skin acted up when I was 9 years old, everything changed.

The other kids at school started to avoid me. I was frequently bullied at school because of my appearance with eczema. The other kids believed I was contagious. I felt isolated and incredibly alone. It wasnt just that I didnt feel beautiful; I also had the sense that nobody wanted to be my friend.

Due to these daily experiences in school, I gradually started to internalize their judgments and began feeling the same way about myself. Every day, I would come home in tears due to the constant bullying I experienced. And before I knew it, I was dealing with all this self-hate. I used to question my own worth a lot. I couldnt even be kind to myself.

Over the years, when I had to deal with my eczema or when I was in a flare, it really affected how I saw myself. How I felt mentally all depended on how bad my skin was at the moment. When my skin was at its worst, I would avoid the mirror or photography altogether. At one point in my preteens/early teens, between 1015 years old, any mirror reflection or photography would freak me out. I was scared that Id see what everyone else saw, and that wasnt a pleasant thought. Looking at myself or catching a glimpse of my reflection felt like a struggle. I was also experiencing extreme anxiety.

I think it all goes back to the awful stuff I went through at school because of my eczema. Those experiences messed with how I saw myself in mirrors. Feeling good about myself was hard. I sometimes still catch myself having this anxiety with mirrors even now as an adult.

Overcoming my negative self-talk and self-hate because of eczema was quite a journey. As a kid, I didnt really get why it was happening. But as I grew older, I redirected my focus toward my strengths. I concentrated on my studies and ensured that I consistently ranked among the top students. Additionally, I engaged in activities I loved, such as skateboarding, spending time with my dog, playing video games, singing and playing music. Relying more on my strengths significantly improved my self-perception.

I honestly dont think I have completely overcome the negative self-talk or the anxiety that comes with it. It is a process that I consistently have to manage and deal with when it happens. In addition to focusing on my strengths and activities I love, I have to constantly remind myself that there is a community of eczema warriors out there too. Im not alone anymore. I make sure that I have a strong support system whenever Im going through the mental struggle of negative self-talk.

For any of my fellow eczema warriors battling with negative self-talk, remember that eczema can come and go. It will never define you. For me, focusing on activities where I knew I excelled really helped me start to embrace my self-worth. Investing my energy into activities I loved also really helped me develop a deeper appreciation for myself and it helped me cultivate self-love. Hopefully that can help you, too.

Read more:
How Eczema Negatively Impacted the Way She Talked to Herself - National Eczema Association

Posted in Eczema | Comments Off on How Eczema Negatively Impacted the Way She Talked to Herself – National Eczema Association

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black … – Dermatology Times

Posted: at 9:58 am

Over the counter (OTC) moisturizer containing 1% colloidal oatmeal was shown to be effective in improving Eczema Area and Severity Index (EASI) scores in Black children after 3 weeks of use,1 Kenvue announced. In 49 children ages 2 to 15 years with mild to moderate atopic dermatitis, the mean change from baseline in EASI score at week 3 was 2.4 (1.7) with the 1% oatmeal cream group compared to a change of 2.1 (2.3) for the prescription barrier cream group.1,2

Kenvue reported the findings at the Science of Skincare Summit in Austin, Texas. The company will also be sharing other industry-advancing science, including solutions in cleansing and hydration from Neutrogena.

In The Power of Oat for Sensitive Skin session on September 23 at 2pm CDT, lead author Tonianne Lisante, Kenvue scientific engagement manager, will detail the findings of the peer-reviewed study that was published in the Journal of Dermatological Treatment highlighting 1% colloidal oatmeal cream used at least twice daily for treating atopic dermatitis in Black children.

When products are not tested in a diverse population, there is a reluctance to accept them as solutions, Lisante said in a press release. A previously published randomized study, conducted in children with atopic dermatitis, also known as eczema, the most common chronic inflammatory skin disease, had already established the safety and efficacy of an OTC 1% colloidal oatmeal cream versus a ceramide-based prescription barrier cream in relieving eczema symptoms in children with mild to moderate eczema. Interestingly, the diverse population included in this study provided a new opportunity to conduct a sub analysis among the group of Black subjects, who we know are more effected by eczema, to help advance community health and solve for public health challenges.1

In the colloidal oatmeal cream group, 100% of patients or participants reported that the cream was appropriate for use on children, and 88% said they would use the cream daily rather than occasionally. Both groups showed improvement in pruritis, skin appearance, dryness/flakiness, and moisturization.2

In her session, Lisante will also review the use of colloidal oatmeal in other products for strengthening the skins moisture barrier, soothing irritated skin, and helping to support the microbiome.

References

Read the original post:
Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black ... - Dermatology Times

Posted in Eczema | Comments Off on Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black … – Dermatology Times

Combination Treatments in HS Require Further Review – Dermatology Times

Posted: at 9:58 am

Key Takeaways

In the treatment of hidradenitis suppurativa (HS), combination treatments have demonstrated varying degrees of efficacy. However, according to a recent review1 of the role of combination therapies in HS, researchers say more evidence is needed stemming from larger, more robust studies of a prospective nature to reaffirm such findings.

The review, published in SKIN: The Journal of Cutaneous Medicine, sought to provide a comprehensive review of combination treatment modalities and their efficacy in patients with HS.

Using electronic databases such as ACP Journal Club, Central Register of Controlled Trials, Cochrane Database of Systemic Reviews, the Database of Abstracts of Review of Effectiveness, and Ovid Medline, investigators Mostafa et al searched for relevant articles published up until May 2023. Studies were eligible for review if they had been published in English, exclusively involved human subjects, and could be classified as case reports, case studies, clinical trials, or cohort studies wherein 2 or more systemic medical therapeutic options were employed in the course of treatment.

Of the 19 studies eligible for review, 12 studies to date have involved the combined use of oral clindamycin and rifampicin, with a typical 600 mg daily dose per drug. Among 3 studies, complete remission of HS was reported, ranging from 1% to 57% of patients achieving remission. Four studies described relapse after cessation of treatment. Side effects involved diarrhea, gastrointestinal problems, and candida vaginitis.

Two of the 19 studies explored the combination of rifampicin-moxifloxacin-metronidazole and found that of 28 patients with HS, 16 individuals achieved clinical remission. Side effects were similar to that of the clindamycin and rifampicin combination, with some reports of moxifloxacin tendinitis, mucosal candidiasis, and asthenia.

Additional combination treatment modalities included the inclusion of an antibiotic, such as in the cases of minocycline and colchicine, clindamycin and ofloxacin, and triamcinolone and lincomycin, among others. Three studies involved non-antibiotic treatments.

Potential study limitations included the quantity of studies included in the review, variance in study outcomes assessed by researchers, and the retrospective or unblinded nature of the eligible studies.

The current evidence depicts combination therapy as a potentially beneficial treatment modality for HS, wrote Mostafa et al. However, the current literature is composed mostly of observational studies and case reports and thus, further research in the form of randomized controlled trials comparing combination treatment to existing interventions is required.

Reference

See the article here:
Combination Treatments in HS Require Further Review - Dermatology Times

Posted in Eczema | Comments Off on Combination Treatments in HS Require Further Review – Dermatology Times

Addressing Misconceptions, Concerns Around Biosimilar Use – Dermatology Times

Posted: at 9:58 am

Research has shown that biosimilars are highly similar to their originator product in terms of safety and efficacy. Misconceptions about biosimilars in the dermatology community and concerns around their use in psoriasis were evaluated with a review of the data to clarify their use; the results were presented in 2 posters.

The rst poster reviewed the biosimilar approval process to clarify dermatologists misconceptions about biosimilars. Dermatologists have approached biosimilar medicines with caution, the researchers wrote.1

A recent Cardinal Health report corroborated the sentiment that dermatologists are hesitant to switch to biosimilars. According to the report, only 31% of dermatologists considered themselves very familiar with biosimilars compared with 81% of gastroenterologists, 76% of rheumatologists, and 33% of ophthalmologists.2

The authors of the first poster presented at the American Academy of Dermatology (AAD) meeting used a PubMed search to identify studies on the molecular design, preclinical and clinical testing requirements, and approval processes of biosimilars. They described how the complexity of biologics means that even batches of innovator biologics can vary during preclinical testing. Biosimilars undergo strict preclinical testing and must demonstrate near similarity to the current originator product in quality factors such as receptor binding and pharmacokinetics, the researchers wrote.1

Although clinical testing is less stringent for a biosimilar compared with the originator product, the purpose of the clinical testing is to conrm the safety and efficacy of the biosimilar. Then, the use of extrapolation allows for biosimilars to be approved for all indications of the originator product without further testing. As a result, the emphasis of biosimilar product testing is on preclinical rather than clinical testing, the authors noted.1

Physicians who recognize that biologics are too complex to duplicate and who desire indication-specic clinical data on biosimilars might be satised knowing biosimilars provide more evidence of similarity than we have for different batches of the innovator product, they concluded. Regulations that are more stringent for biosimilars than for different batches of innovator products may not be logical.1

In the second poster, researchers addressed concerns about the use of biosimilars approved to treat psoriasis using extrapolated evidence from other diseases. They compared efficacy/effectiveness, safety, and drug survival of biosimilars to treat plaque psoriasis with originator products using data from 13 randomized controlled trials (RCTs) and 3 cohort studies. Of the RCTs, 10 were for adalimumab, 2 were for etanercept, and 1 was for iniximab. Of the cohort studies, 1 was for adalimumab, 1 was for etanercept, and 1 was for both etanercept and iniximab.3

Eleven trials compared biosimilars with the originator in patients who had never been on the originator product (initiators); 9 trials analyzed switching from the originator product to the biosimilar (switchers). The initiator trials all had similar rates of 75% improvement in the Psoriasis Area and Severity Index and similar adverse events by week 16. The switched trials also had similar outcomes by week 52.3

One of the cohort studies reported more adverse events among the group of adalimumab patients switching from the originator to the biosimilar, although the other 2 cohort studies showed no signicant differences in safety and effectiveness. The majority of available evidence suggests similarities between biosimilars and originators, the researchers concluded. Future pharmacovigilance studies are needed to evaluate the long-term, real-world use of biosimilars for psoriasis treatment.3

References

Original post:
Addressing Misconceptions, Concerns Around Biosimilar Use - Dermatology Times

Posted in Eczema | Comments Off on Addressing Misconceptions, Concerns Around Biosimilar Use – Dermatology Times

Native American and Indigenous Communities Face Dermatologic … – Dermatology Times

Posted: at 9:58 am

Key Takeaways

Access to medical care has been a persistent challenge for individuals within the Native and Indigenous communities, and this issue persists when it pertains to dermatological healthcare for this patient demographic. Despite increasing evidence of health status inequities affecting Indigenous populations, health services often fail to address health and social inequities as routine aspects of health care delivery, according to authors of a 2016 ethnographic study.1

Globally health and well-being of the Indigenous community falls significantly behind that of the general population, with life expectancy projected to be dramatically shorter than average.1 These challenges are compounded by discriminatory and stigmatizing experiences faced by Native and Indigenous individuals worldwide.

Research confirms that Indigenous peoples experience individual and systemic discrimination when seeking health care, despite efforts within the health care sector to promote cultural sensitivity and cultural safety, according to Browne et al.1 Health services, however, are not typically designed to take into account the experiences of Indigenous peoples. For example, despite extensive evidence linking trauma and violence to multiple health problems, including chronic pain, depression, anxiety and substance use, these dynamics are rarely considered in the design and delivery of health care for Indigenous peoples.

In Canada in particular, it is estimated that the one-year prevalence of atopic dermatitis (AD) in children living on a First Nations reserve could reach upwards of 16.5%. Most cases are classified as moderate to severe in nature.2

Additionally, research suggests that other common cutaneous conditions among members of the Indigenous communities include impetigo, skin infections, diabetic skin complications and ulcers, infestations, pediculosis capitis, psoriasis, and scabies, all of which are seen in significantly high rates, with some patients experiencing more than one condition at once.2

Environmental factors such as clean water concerns, access to and cost of skin care regimens and products, crowded living conditions, and poverty are contributors to exacerbation of skin conditions, such as AD.2

Furthermore, skin cancer prevention efforts among Native and Indigenous individuals are lacking, according to the American Academy of Dermatology (AAD).3

A 2022 study4 published in the Journal of the American Academy of Dermatology found that among the more than 9 million American Indians and Alaska Natives (AIAN) living in the United States, research and prevention efforts related to skin cancer in this population are scarce. To date, this is the largest study to explore skin cancer education, prevention, and research efforts in this patient population.3

When you look at the lack of sun protection and use of tanning beds, its not surprising to see that American Indians/Alaskan Natives are reporting more severe sun damage to their skin, such as sunburns, when spending over an hour in the sun as compared to non-white respondents, said Vinod E. Nambudiri, MD, MBA, FAAD, in a press release from the AAD.3Nambudiri is a co-author of the study.

While some people may be most concerned about the freckles, age spots and wrinkles that develop on their skin from UV exposure, its the increasing risk of skin cancer, including melanoma, the deadliest form of skin cancer, which is the most alarming, Nambudiri said.

According to an examination of data from the 2020 US Census, a total of 56 dermatologists and 3 dermatology physician assistants are located within the 100 most populous AIAN homelands. For a population that experiences increased acne scarring and mortality associated with melanoma,5 these numbers are alarming.

With decreased accessibility to dermatologic care and other factors such as cultural differences, disproportionate poverty, transportation, and inadequate health literacy, researchers say there are several factors contributing to poor skin health outcomes in this patient population.5

Another study6 found that access to dermatologic care and telehealth programs was hindered by rural living. The study found that on average, the nearest dermatology clinic from rural communities lived in predominantly by American Indian individuals was 68 miles. Of all tribal facilities and rural Indian Health Services in the continental US (n = 303), only 9% had access to a teledermatology program.6

References

View original post here:
Native American and Indigenous Communities Face Dermatologic ... - Dermatology Times

Posted in Eczema | Comments Off on Native American and Indigenous Communities Face Dermatologic … – Dermatology Times

Microwave Therapy Successful for Treating Warts in Children – Dermatology Times

Posted: at 9:58 am

In 35 pediatric patients with recalcitrant warts, 68.6% experienced complete resolution after an average of 3 microwave treatment sessions.1 Patients who responded to microwave treatment required an average of 3 sessions (range: 2-8) for complete resolution. The average age of the warts was 29 months (6 to 84 months) and most patients (94%) had failed alternative treatments.

Researchers reviewed the case notes of patients treated at a tertiary dermatology unit where hypothermia was induced using Swift through repeated applications that lasted 1 to 2 seconds. Energy was supplied at a frequency of 8 GHz and an average power of 7W. Each wart was treated with microwave therapy an average of 4 times at each visit.

Following the initial treatment, follow-up sessions were scheduled approximately every 4 weeks for assessment and to determine if additional treatments were needed. Eight of the 35 patients did not tolerate microwave treatment due to pain and discontinued treatments.

Plantar warts are generally more resistant to therapy than common warts. In the study cohort, 20 patients presented with plantar warts and clearance was achieved in 14 (70%) of those cases. This compares favourably to traditional treatments such as salicylic acid (31%) and cryotherapy (34%)and is consistent with previous rates of clearance using microwave therapy in adults.

Treatment with cantharadin 1%, podophyllin 20%, and salicylic acid 30% solution showed an 86.5% clearance rate for all warts in children but adverse events such as blistering occurred in 41.2% of patients. Microwave treatments did not cause ulceration or blistering but did cause short-term pain during treatment that resulted in some patients discontinuing treatments.

Microwave treatment of warts has advantages, including no pre-treatment preparation and no special dressings or precautions following treatment. Each application takes approximately 2 seconds and most patients required only 4 sessions. No scarring or pigmentary changes were reported.

Limitations of the study included the retrospective study design and an absence of head-to-head comparisons. Authors determined that microwave treatment is asuccessful optionfor clearing recalcitrant warts in children.

Reference

Read the original:
Microwave Therapy Successful for Treating Warts in Children - Dermatology Times

Posted in Eczema | Comments Off on Microwave Therapy Successful for Treating Warts in Children – Dermatology Times

9 Best Antifungal Body Washes Review – The Jerusalem Post

Posted: at 9:58 am

Our Top Picks

If you're looking for relief from skin irritations and fungal infections, antifungal body wash can be incredibly beneficial. After researching and testing various products, we've found the best antifungal body washes on the market. It's important to choose a product that is effective in treating fungal infections and gentle on the skin. The scent is also a factor to consider, as many antifungal body washes have a medicinal smell. Our top-ranked products offer a range of benefits, from effectiveness to gentle formulas to pleasant scents. If you suffer from skin irritations or fungal infections, our recommendations are a great place to start your search.

The Antifungal Antibacterial Soap & Body Wash is a natural solution for a variety of fungal and bacterial skin conditions. Made with tea tree oil, it effectively treats jock itch, athlete's foot, nail fungus, ringworm, and even eczema and back acne. The 8-ounce bottle is the perfect size for daily use, and the natural ingredients make it safe for all skin types. Say goodbye to uncomfortable and embarrassing skin conditions with this powerful body wash.

Rated 9.8 based on 10

JPOST

Pros

Natural ingredients, Effective against multiple conditions, Can be used on body and feet

Cons

Strong tea tree scent

The Antifungal Body Wash & Soap is a versatile solution for a range of skin issues. Made with tea tree oil and other natural ingredients, it effectively combats fungal infections, bacteria, and body odor. This body wash can be used for tinea versicolor, back acne, folliculitis, jock itch, ringworm, and athlete's foot. It's gentle enough for daily use and comes in a convenient pump bottle. Customers rave about its effectiveness and pleasant scent, making it a must-have for anyone dealing with these skin concerns.

Rated 9.4 based on 10

JPOST

Pros

Effective against various conditions, Contains tea tree oil, Gentle on skin

Jivi Antifungal Body Wash is a powerful solution for treating various fungal infections such as athlete's foot, toenail fungus, ringworm, jock itch, and more. Made with tea tree oil and other natural ingredients, this body wash effectively eliminates fungal growth while nourishing and moisturizing the skin. Its 12 fl oz size makes it ideal for daily use, and its green packaging is eco-friendly. With Jivi Antifungal Body Wash, you can say goodbye to pesky fungal infections and hello to healthy, glowing skin.

Rated 9.2 based on 10

JPOST

Pros

Treats various fungal infections, Contains natural tea tree oil, Gentle on skin

Cons

Scent might not be preferred

The Signature Black Bottle Body Wash is a clinically proven antifungal soap that effectively treats common skin conditions such as jock itch, athlete's foot, and ringworm. Infused with tea tree oil, this body wash is gentle on the skin while still being tough on fungus. The 9 oz. bottle is the perfect size for everyday use and the rich lather leaves skin feeling clean and refreshed. Say goodbye to stubborn skin conditions with the Signature Black Bottle Body Wash.

Rated 8.8 based on 10

JPOST

Pros

Clinically effective ingredients, Tea tree oil for skin, Effective against various infections

Cons

Strong medicinal scent

Truremedy Naturals Remedy Soap Tea Tree Oil Antibacterial Body Soap is a powerful antifungal body wash that helps with a variety of skin issues such as body odor, athlete's foot, jock itch, ringworm, yeast infections, and other skin irritations. Made with all-natural ingredients including tea tree oil, eucalyptus oil, and peppermint oil, this body wash is gentle on the skin while still providing effective relief. The 12 oz bottle is the perfect size for daily use and the convenient pump makes it easy to dispense. Say goodbye to uncomfortable skin issues with Truremedy Naturals Remedy Soap.

Rated 8.5 based on 10

JPOST

Pros

Antibacterial and antifungal, Helps with various skin issues, Contains tea tree oil

LOVE, LORI Tea Tree Body Wash is a must-have for anyone looking to improve their skin health. This 12oz bottle of antibacterial body wash is not only effective against jock itch and athlete's foot, but also helps treat acne and eczema. The tea tree oil in this antifungal soap and shower gel provides a refreshing and invigorating scent while also providing powerful cleansing properties. This product is perfect for anyone who wants to feel clean and refreshed after a shower, while also improving their overall skin health.

Rated 8.4 based on 10

JPOST

Pros

Antibacterial and antifungal properties, Helps with jock itch and athletes foot, Can improve acne and eczema

Cons

May not work for everyone

The New York Biology Tea Tree Body Wash is a must-have for anyone looking for a moisturizing and soothing body wash. Perfect for both men and women, this body wash helps with a variety of skin concerns, including itchy skin, jock itch, athletes foot, nail fungus, eczema, body odor, and ringworm. With its natural ingredients and 16 fl oz size, it is a great value for anyone looking for a high-quality body wash.

Rated 8 based on 10

JPOST

Pros

Soothes itchy skin, Helps with multiple conditions, Moisturizes body

Cons

Strong tea tree scent

The DERMOIA Eczema Body Wash for Adults is an excellent choice for those with sensitive skin. With its hypoallergenic and fragrance-free formula, this tea tree body wash is gentle yet effective in treating eczema and jock itch. The 1.00 pound pack of 1 is perfect for daily use and is suitable for both men and women. Its antifungal properties make it a go-to product for those with skin conditions, and its natural ingredients ensure it's safe for prolonged use. Overall, the DERMOIA Eczema Body Wash for Adults is a great investment for anyone looking for a reliable and effective body wash.

Rated 7.7 based on 10

JPOST

Pros

Antifungal properties, Hypoallergenic and fragrance-free, Suitable for sensitive skin

Cons

May not work for everyone

If you're looking for an effective solution to treat toenail fungus, look no further than the Toenail Fungus Treatment - Body and Foot Antifungal Wash. This potent formula is designed to eliminate fungus and odors, while also treating conditions like athlete's foot, ringworm, and jock itch. Made with natural and safe ingredients, this antifungal wash is easy to use and can help restore the health and appearance of your feet and nails. So why suffer with unsightly and uncomfortable fungal infections when you can use this powerful treatment to get relief? Try it today and see the results for yourself!

Rated 7.5 based on 10

JPOST

Pros

Effective against various fungi, Soothes and moisturizes skin, Eliminates foot odor

Cons

May require consistent use

Q: What is an antifungal body wash?

A: An antifungal body wash is a type of soap that is formulated to specifically target and eliminate fungal infections on the skin. It contains active ingredients like tea tree oil, ketoconazole, and selenium sulfide that work to kill fungus and prevent it from spreading.

Q: Who should use antifungal body wash?

A: Antifungal body wash is recommended for anyone who is experiencing a fungal infection on their skin. This can include athletes who are prone to fungal infections from sweating, people who have compromised immune systems, and individuals who have been diagnosed with a fungal skin condition like ringworm or jock itch.

Q: How do I use antifungal body wash?

A: To use antifungal body wash, wet your skin and apply a small amount of the soap to a washcloth or loofah. Gently lather the soap onto your skin, paying special attention to areas that are prone to fungal infections like your feet, groin, and armpits. Rinse thoroughly with warm water and pat your skin dry. Use the body wash daily until your fungal infection has cleared up, and then continue to use it as a preventative measure.

After conducting thorough research and analysis of various antifungal body wash products, it is clear that this category offers a range of options for individuals looking to combat fungal infections and skin irritations. Many of the reviewed products contain tea tree oil, which is known for its antifungal and antibacterial properties. While some products are specifically targeted towards certain conditions such as athlete's foot or jock itch, others offer moisturizing and gentle cleansing for dry and sensitive skin. Overall, we encourage readers to consider incorporating antifungal body wash into their hygiene routine and to choose a product that fits their individual needs.

Read more here:
9 Best Antifungal Body Washes Review - The Jerusalem Post

Posted in Eczema | Comments Off on 9 Best Antifungal Body Washes Review – The Jerusalem Post

Page 11234..1020..»